Roadmap for implementation of quality by design (QbD) for biotechnology products.

Quality by design (QbD) has been receiving a lot of attention in the pharmaceutical community of late. Successful QbD implementation requires a thorough understanding of the relationship between the critical quality attributes (CQAs) and the clinical properties of the product, the relationship between the process and CQAs and the variability in raw materials. This article presents a roadmap for successful QbD implementation for therapeutic biotechnology products. The approach presented here is aligned with existing regulatory guidance documents. Key developments are reviewed and case studies are used to illustrate these concepts. It is concluded that although several QbD concepts are being practiced by the biotechnology industry, successful dialogue and partnership between the industry and its regulators will be the key to successful QbD implementation.

[1]  Anurag S. Rathore,et al.  Design space for biotech products , 2007 .

[2]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[3]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[4]  Anurag S Rathore,et al.  Using Statistical Analysis for Setting Process Validation Acceptance Criteria for Biotech Products , 2007, Biotechnology progress.

[5]  A. Rathore,et al.  Application of Multivariate Data Analysis for Identification and Successful Resolution of a Root Cause for a Bioprocessing Application , 2008, Biotechnology progress.

[6]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[7]  C. Schneider,et al.  Toward biosimilar monoclonal antibodies , 2008, Nature Biotechnology.

[8]  Susan Cook,et al.  Quality by Design in the CMO Environment , 2007 .

[9]  Michael Butler,et al.  Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals , 2005, Applied Microbiology and Biotechnology.

[10]  Roger Nosal,et al.  PQLI Key Topics - Criticality, Design Space, and Control Strategy , 2008, Journal of Pharmaceutical Innovation.

[11]  Xiangyang Wang,et al.  Case Study on Definition of Process Design Space for a Microbial Fermentation Step , 2008 .

[12]  R. Senger,et al.  Effect of Shear Stress on Intrinsic CHO Culture State and Glycosylation of Recombinant Tissue‐Type Plasminogen Activator Protein , 2008, Biotechnology progress.

[13]  Xiangyang Wang,et al.  Defining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation , 2008, Biotechnology progress.

[14]  Lawrence X. Yu,et al.  Applications of process analytical technology to crystallization processes. , 2004, Advanced drug delivery reviews.

[15]  W. Ebling,et al.  Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist. , 2007, Journal of pharmaceutical and biomedical analysis.

[16]  J. Munson,et al.  A Review of Process Analytical Technology (PAT) in the U.S.Pharmaceutical Industry , 2006 .

[17]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[18]  James L. Vesper.  Assessing and managing risks in a GMP environment , 2005 .

[19]  Anika Ashok,et al.  ICH Harmonised Tripartite Guideline , 2009 .

[20]  Anurag S Rathore,et al.  Case study and application of process analytical technology (PAT) towards bioprocessing: Use of on‐line high‐performance liquid chromatography (HPLC) for making real‐time pooling decisions for process chromatography , 2008, Biotechnology and bioengineering.

[21]  Richard A. Wolfe,et al.  A Rational Approach for Setting and Maintaining Specifications for Biological and Biotechnology-Derived Products Part 1 , 2008 .

[22]  S Gnoth,et al.  Process Analytical Technology (PAT): batch-to-batch reproducibility of fermentation processes by robust process operational design and control. , 2007, Journal of biotechnology.

[23]  Maureen Lanan.  QbD for Raw Materials , 2008 .

[24]  Jean-Francois Denault.  Ollihoring to China : What should your model be? , 2006 .

[25]  Kingman Ng,et al.  Application of Quality by Design and Risk Assessment Principles for the Development of Formulation Design Space , 2008 .

[26]  David Chilin,et al.  Applying process analytical technology to biotech unit operations , 2006 .

[27]  Kripa Ram,et al.  Using a Risk Assessment Process to Determine Criticality of Product Quality Attributes , 2008 .

[28]  John Lepore,et al.  PQLI Design Space , 2008, Journal of Pharmaceutical Innovation.

[29]  Jeremy S. Conner,et al.  Application of Multivariate Analysis toward Biotech Processes: Case Study of a Cell‐Culture Unit Operation , 2007, Biotechnology progress.

[30]  Steven L. Nail,et al.  Elements of Quality by Design in Development and Scale-Up of Freeze-Dried Parenterals , 2008 .

[31]  Douglas Cecchini.  Applications of Design Space for Biopharmaceutical Purification Processes , 2008 .

[32]  Steven Kozlowski,et al.  Current and future issues in the manufacturing and development of monoclonal antibodies. , 2006, Advanced drug delivery reviews.

[33]  Roger Nosal,et al.  PQLI Definition of Criticality , 2008, Journal of Pharmaceutical Innovation.

[34]  Marian Kelley,et al.  Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. , 2007, Journal of immunological methods.

[35]  J. Neway.  How to Make the Business Case for Quality by Design , 2008 .

[36]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[37]  Cenk Undey,et al.  Monitoring of Biopharmaceutical Processes: Present and Future Approaches , 2009 .

[38]  Steven Kozlowski,et al.  Considerations for Biotechnology Product Quality by Design , 2008 .

[39]  Peter K. Watler,et al.  Application of QbD Principles to Tangential Flow Filtration Operations , 2008 .